Scientists discover endogenous dendritic cell-derived interleukin-27 promotes tumor growth

In a new report published in the Journal of Leukocyte Biology, scientists lay the groundwork for the development of novel tumor therapies that may help rid the body of cancer by inhibiting the recruitment of a specific suppressive immune cell type called "regulatory T-cells." The approach described in the report shows that an immune molecule, called interleukin-27, promotes the recruitment of regulatory T-cells. This suggests that by stopping IL-27's immunosuppressive function, cancer therapies can more effectively activate other T-cells to attack and destroy cancer tumors.

"Our study not only provides a new insight into the effects of interleukin-27 in regulatory T-cell biology, but also greatly improves our understanding of the physiological functions of interleukin-27, especially in tumor immunology," said Siyuan Xia, a researcher involved in the work from the State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, China. "We hope our study could shed new light on developing novel interventional therapies by targeting regulatory T-cells in cancer patients."

Scientists made this discovery by using mice deficient in a specific subunit of interleukin-27 called p28. They compared the tumor infiltrating lymphocytes between interleukin-27 p28 deficient mice and normal mice, and through their experiments, found a significant decrease of regulatory T cells, and other key immune mediators in the absence of interleukin-27 p28.

"Suppressive and regulatory pathways in the immune system are incredibly important for normal health and preventing autoimmunity," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "However, these pathways also get exploited by cancer to prevent immune responses leading to cancer progression. The current studies point to an important regulatory network centered on interleukin-27 that could be targeted to improve immunity to cancer in humans."

add to favorites email to friend print save as pdf

Related Stories

New nanoparticle that only attacks cervical cancer cells

Mar 17, 2014

One of the most promising technologies for the treatment of various cancers is nanotechnology, creating drugs that directly attack the cancer cells without damaging other tissues' development. The Laboratory ...

Slowing down the immune system when in overdrive

Feb 10, 2014

Many people suffer from chronic inflammation because their immune systems overreact to 'self' tissue. Sydney scientists believe that a small molecule known as Interleukin 21 is a promising therapeutic target in such cases.

New mechanism for unleashing immune system against cancer

Apr 07, 2014

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators ...

Cancer vaccine could use immune system to fight tumors

Feb 27, 2014

Cincinnati Cancer Center (CCC) and UC Cancer Institute researchers have found that a vaccine, targeting tumors that produce a certain protein and receptor responsible for communication between cells and the body's immune ...

Recommended for you

Video: Is that double mastectomy really necessary?

18 hours ago

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments